×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Maps
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Cantor Fitzgerald Maintains Soleno Therapeutics (SLNO) Overweight Recommendation
MSN
Fintel reports that on September 26, 2023, Cantor Fitzgerald maintained coverage of Soleno Therapeutics (NASDAQ:SLNO) with a Overweight recommendation.
10 hours ago
Soleno Therapeutics Stands with the Prader-Willi Syndrome Community
GlobeNewswire
REDWOOD CITY, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Nasdaq: SLNO), (“Soleno” or the “Company”),...
2 days ago
Painful week for private equity firms invested in Soleno Therapeutics, Inc. (NASDAQ:SLNO) after 8.5% drop, institutions also suffered losses
Simply Wall Street
Key Insights The considerable ownership by private equity firms in Soleno Therapeutics indicates that they collectively...
3 days ago
Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
Yahoo Finance
REDWOOD CITY, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical...
1 week ago
Wilson Sonsini Advises Soleno Therapeutics on $138 Million Public Offering
Wilson Sonsini
On May 2, 2024, Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of...
1 week ago
Oppenheimer cuts Soleno Therapeutics stock target By Investing.com
Investing.com
On Monday, Oppenheimer adjusted its price target for Soleno Therapeutics (NASDAQ:SLNO), a biopharmaceutical company, reducing it to $59 from...
4 days ago
Soleno Therapeutics Gets Breakthrough Therapy Designation for Diazoxide Choline
Morningstar
By Chris Wack. Soleno Therapeutics said that the Food and Drug Administration has granted Breakthrough Therapy Designation for diazoxide...
2 weeks ago
Why Soleno Therapeutics Stock Is Skyrocketing Today
The Motley Fool
Soleno Therapeutics ... The clinical-stage biotech company received great news from the FDA. Shares of Soleno Therapeutics (SLNO -0.07%) were...
2 weeks ago
Soleno Therapeutics reports Q1 EPS (59c), consensus (37c) - TipRanks.com
Tipranks
Reports that as of March 31 Soleno had $42.8M of cash and cash equivalents, $106.8M of short-term investments, and $8.8M of long-term investments.
4 days ago
Soleno Therapeutics Receives Breakthrough Therapy Designation from U.S. FDA for DCCR (Diazoxide Choline ...
GlobeNewswire
First Ever Breakthrough Designation for a Drug Being Developed for PWS Designation is Based on Data from the Phase 3 Program for DCCR...
2 weeks ago